Aromatherapy as an adjunctive therapy for neonatal abstinence syndrome: A pilot study.
OBJECTIVE: To determine if aromatherapy added to the current standard of care for opioid withdrawal syndrome decreases hospitali-zation and need for opioid replacement in neonates.
DESIGN: Nonblinded, randomized control trial.
SETTING: Level 4 neonatal intensive care unit (NICU).
PATIENTS AND PARTICIPANTS: Thirty eight patients met inclusion criteria of greater than or equal to 36 weeks of gestation, history of in-trauterine opioid exposure, primary diagnosis of neonatal abstinence syndrome (NAS), and parental permission to participate.
INTERVENTIONS: Infants were randomized to either a standard therapy group or a standard therapy plus aromatherapy.
MAIN OUTCOME MEASURE(S): Duration of therapy and length of stay.
RESULTS: Our pilot study showed that the use of aromatherapy in conjunction with standard therapy reduced the duration of medica-tion treatment by 41 percent and hospital length of stay in the NICU by 36 percent.
CONCLUSIONS: The use of aromatherapy appears to help mitigate symptoms of NAS and offers to be a viable treatment modality when used with conventional therapy.
J Opioid Manag
Daniel, J. M., Davidson, L. N., Havens, J. R., Bauer, J. A., Shook, L. A. Aromatherapy as an adjunctive therapy for neonatal abstinence syndrome: A pilot study. J Opioid Manag 16, 119-125 (2020).